通过NF-κB通路,GNL3L表现出促瘤活动,作为急性髓性白血病的不良预后因素
Ji Li1, Zhimin Wu2, Yipeng Pan3
1Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Journal of Cancer
|July 1, 2024
概括
关氨酸核酸结合蛋白样3-样蛋白 (GNL3L) 是急性髓性白血病 (AML) 的预后不良因素. GNL3L促进AML的进展和化学抵抗,建议它作为潜在的治疗点.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性髓性白血病 (AML) 的预后不好,治疗选择有限.
- 在40%的AML患者中观察到核因子kappa B (NF-κB) 活性升高,强调NF-κB作为治疗点.
- 关氨酸核酸结合蛋白样3-样蛋白 (GNL3L) 是一种新发现的瘤基因,在各种癌症中激活NF-κB.
研究的目的:
- 调查GNL3L在AML中的作用和预后意义.
- 探索GNL3L对NF-κB通路激活和AML细胞行为的影响.
- 评估GNL3L作为AML的潜在治疗点.
主要方法:
- 在三个独立的AML患者队列中对GNL3L表达的全面分析.
- 评估GNL3L对RELA活动和NF-κB通路的影响.
- 评估GNL3L对AML细胞增殖,细胞亡和细胞氨基酸耐药性的影响.
主要成果:
- GNL3L表达被确定为AML的不良预后因素.
- 发现GNL3L可以增强RELA活动并激活NF-κB通路.
- GNL3L促进了AML细胞的扩散,抑制了细胞灭亡,并赋予了对cytarabine的耐药性.
结论:
- 在AML的发病过程中,GNL3L发挥着重要作用.
- 在AML患者中,GNL3L与不良结果和化学抵抗有关.
- 在AML治疗中,GNL3L是一个有前途的治疗标.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
The Nucleolus
8.8K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.8K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K


